Taysha Gene Therapies (TSHA) EBIT (2020 - 2026)
Taysha Gene Therapies (TSHA) posted EBIT of -$43.5 million for Q1 2026, down 53.66% sequentially from -$28.3 million in Q4 2025, and down 103.01% YoY from $1.4 billion in Q1 2025.
Taysha Gene Therapies (TSHA) EBIT (2020 - 2026) Analysis & Trends
Taysha Gene Therapies has reported EBIT for 7 years, with the latest figure at -$43.5 million in Q1 2026.
- Quarterly EBIT fell 103.01% year-over-year to -$43.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$132.6 million (down 49.7% YoY) and the FY2025 annual result came in at -$110.5 million, down 20.82% from the prior year.
- EBIT slipped to -$43.5 million in Q1 2026 per TSHA's latest filing, from -$28.3 million in the prior quarter.
- Over five years, EBIT peaked at -$16.2 million in Q4 2023 and troughed at -$54.0 million in Q4 2022.
- A 5-year average of -$28.3 million and a median of -$25.5 million in 2022 frame the typical range for EBIT.
- The sharpest annual moves came in 2023 and 2026: EBIT surged 69.9% in 2023, then tumbled 103.01% in 2026.
- Over 5 years, EBIT stood at -$54.0 million in 2022, then surged by 69.9% to -$16.2 million in 2023, then declined by 22.69% to -$19.9 million in 2024, then tumbled by 41.98% to -$28.3 million in 2025, then slumped by 53.66% to -$43.5 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$43.5 million, -$28.3 million, and -$34.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | -47.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -47.35 Mn |
| Mar 31, 2026 | -43.49 Mn |
| Dec 31, 2025 | -28.30 Mn |
| Sep 30, 2025 | -34.02 Mn |
| Jun 30, 2025 | -26.75 Mn |
| Mar 31, 2025 | -21.42 Mn |
| Dec 31, 2024 | -19.93 Mn |
| Sep 30, 2024 | -25.90 Mn |
| Jun 30, 2024 | -21.30 Mn |
| Mar 31, 2024 | -24.33 Mn |
| Dec 31, 2023 | -16.25 Mn |
| Sep 30, 2023 | -16.25 Mn |
| Jun 30, 2023 | -23.38 Mn |
| Mar 31, 2023 | -16.56 Mn |
| Dec 31, 2022 | -53.97 Mn |
| Sep 30, 2022 | -25.46 Mn |
| Jun 30, 2022 | -33.37 Mn |
| Mar 31, 2022 | -49.65 Mn |
| Dec 31, 2021 | -49.72 Mn |
| Sep 30, 2021 | -50.68 Mn |